Free Trial Information
BioCentury | Apr 8, 2013
Company News

DFH Pharma, Hetero Group deal

...to develop second-generation HIV maturation inhibitors (see BioCentury, Jan. 16, 2012 & April 23, 2012). DFH Pharma Inc....
Read More
BioCentury | Apr 3, 2013
Company News

DFH, Hetero partner for HIV maturation inhibitors

DFH Pharma Inc. (Gaithersburg, Md.) partnered with Hetero Group (Hyderabad, India) to discover and develop second-generation HIV maturation inhibitors to treat all HIV strains. The compounds block maturation of the HIV gag polyprotein . Hetero will...
Read More
BioCentury | Apr 23, 2012
Company News

DFH Pharma deal

...IND submission. DFH will own the resulting IP from the deal. Details were not disclosed. DFH Pharma Inc....
Read More
BioCentury | Jan 16, 2012
Company News

CiVentiChem, DFH Pharma deal

...of compounds with maturation inhibition activity. Details were not disclosed. CiVentiChem LLC , Cary, N.C. DFH Pharma Inc....
Read More
BioCentury | Jan 16, 2012
Company News

DFH Pharma, National Cancer Institute deal

...The institute partnered with DFH Pharma to develop second-generation inhibitors of the maturation of HIV gag polyprotein...
...HIV infection, with an option to license worldwide commercialization rights (see BioCentury, Nov. 21, 2011). DFH Pharma Inc....
Read More
BioCentury | Nov 21, 2011
Company News

DFH Pharma deal

...polyprotein . DFH has an option to license worldwide commercialization rights. Details were not disclosed. DFH Pharma Inc....
Read More
Items per page:
1 - 6 of 6
BioCentury | Apr 8, 2013
Company News

DFH Pharma, Hetero Group deal

...to develop second-generation HIV maturation inhibitors (see BioCentury, Jan. 16, 2012 & April 23, 2012). DFH Pharma Inc....
Read More
BioCentury | Apr 3, 2013
Company News

DFH, Hetero partner for HIV maturation inhibitors

DFH Pharma Inc. (Gaithersburg, Md.) partnered with Hetero Group (Hyderabad, India) to discover and develop second-generation HIV maturation inhibitors to treat all HIV strains. The compounds block maturation of the HIV gag polyprotein . Hetero will...
Read More
BioCentury | Apr 23, 2012
Company News

DFH Pharma deal

...IND submission. DFH will own the resulting IP from the deal. Details were not disclosed. DFH Pharma Inc....
Read More
BioCentury | Jan 16, 2012
Company News

CiVentiChem, DFH Pharma deal

...of compounds with maturation inhibition activity. Details were not disclosed. CiVentiChem LLC , Cary, N.C. DFH Pharma Inc....
Read More
BioCentury | Jan 16, 2012
Company News

DFH Pharma, National Cancer Institute deal

...The institute partnered with DFH Pharma to develop second-generation inhibitors of the maturation of HIV gag polyprotein...
...HIV infection, with an option to license worldwide commercialization rights (see BioCentury, Nov. 21, 2011). DFH Pharma Inc....
Read More
BioCentury | Nov 21, 2011
Company News

DFH Pharma deal

...polyprotein . DFH has an option to license worldwide commercialization rights. Details were not disclosed. DFH Pharma Inc....
Read More
Items per page:
1 - 6 of 6